<DOC>
	<DOCNO>NCT00657267</DOCNO>
	<brief_summary>Temozolomide ( Temodar ) FDA approve medication treatment newly diagnose glioblastoma . In study , use temozolomide treat recurrent glioblastoma . We use different dose schedule FDA approve dose schedule . The purpose study determine patient fail standard temozolomide treatment respond temozolomide give different dose schedule ( 21 day every 28 day ) .</brief_summary>
	<brief_title>Dose-Intense Temozolomide Recurrent Glioblastoma</brief_title>
	<detailed_description>- Participants give medication-dosing calendar treatment cycle . Each treatment cycle last 4 week ( 28 day ) time take temozolomide orally day first three week . - At end cycle ( day 28 , +/- 2 day ) , follow procedure perform : Complete physical examination include neurological exam ; vital sign ; review current medication symptom ; blood sample ; pregnancy test woman child-bearing potential ; self-administered quality life questionnaire ; brain MRI CT scan . - Participants may continue take temozolomide tumor grows experience unacceptable side effect .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Must provide independent consent must demonstrate willingness participate study adhere dose visit schedule . 18 year age old ( either sex , race ) Histologic diagnosis GBM gliosarcoma unequivocal progression MRI CT scan Must receive standard combine modality therapy firstline treatment consist RT plus concomitant temozolomide follow adjuvant temozolomide ( least 2 cycle adjuvant temozolomide ) Gadolinium MRI contrast CT scan must obtain within 14 day prior registration , must steroid dose stable least 5 day . Karnofsky Performance status 60 great Life expectancy least 8 week Recovered toxic effect prior therapy , 21 day must elapse since prior treatment temozolomide If patient residual toxicity previous treatment , toxicity must â‰¤ Grade 1 Laboratory test within parameter outline protocol Female subject childbearing potential &amp; male subject female partner childbearing potential must agree use medically accept method contraception surgically sterilize prior Screening , receive protocolspecified medication , 30 day stop study medication Negative pregnancy test within 48 hour prior dose study drug ( female subject childbearing potential ) Free clinically relevant disease would , Principal Investigator 's opinion , interfere conduct study study evaluation Must able adhere dose visit schedule , agree record medication time , concomitant medication , adverse event ( AEs ) accurately consistently daily diary Unstained slide ( least 15 10 micron thickness , 20 &lt; 10 micron thickness ) 1 tissue block must available original diagnostic biopsy/surgery biopsy/surgery recurrence Participants undergone recent resection recurrent progressive tumor eligible provide least 2 week elapse since surgery , subject recover surgicalrelated trauma Residual disease follow resection recurrent GBM gliosarcoma mandate eligibility study . Participant receive dose schedule temozolomide 75 mg/m2/day 42 day RT follow adjuvant temozolomide dose 150200 mg/m2/day 5 day 28day schedule ( standard dose adjustment toxicity allow ) Any antitumor agent standard surgical resection , RT temozolomide prior enrollment study period Received treatment BCNU ( Gliadel ) wafers GliaSite Progressed prior receive least 2 cycle adjuvant temozolomide Pregnant intend become pregnant study In situation condition , opinion Investigator , may interfere optimal participation study Participating clinical study investigational drug prescribe Allergic sensitivity study drug excipients History cancer ( except nonmelanoma skin cancer carcinoma situ cervix ) , unless he/she complete remission receive treatment particular disease past 3 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>recurrent glioblastoma</keyword>
	<keyword>temodar</keyword>
	<keyword>temozolomide</keyword>
</DOC>